News
ERNA
2.050
+9.04%
0.170
Weekly Report: what happened at ERNA last week (1102-1106)?
Weekly Report · 11h ago
Weekly Report: what happened at ERNA last week (1026-1030)?
Weekly Report · 11/02 10:14
Weekly Report: what happened at ERNA last week (1019-1023)?
Weekly Report · 10/26 10:13
Weekly Report: what happened at ERNA last week (1012-1016)?
Weekly Report · 10/19 10:13
Eterna Therapeutics Updates Investor Presentation and Disclosures
TipRanks · 10/15 21:48
Weekly Report: what happened at ERNA last week (1005-1009)?
Weekly Report · 10/12 10:18
Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8
Benzinga · 10/06 12:57
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/06 12:05
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Barchart · 10/06 07:55
Weekly Report: what happened at ERNA last week (0928-1002)?
Weekly Report · 10/05 10:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/02 12:05
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
Barchart · 09/30 15:30
Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND
NASDAQ · 09/30 13:12
Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101
TipRanks · 09/30 12:50
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Benzinga · 09/30 12:40
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/30 12:05
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Barchart · 09/30 07:32
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/29 21:06
Ernexa Selected For Emerging Track At 2026 Cell & Gene Meeting On The Mesa
NASDAQ · 09/29 15:06
Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting
TipRanks · 09/29 13:36
More
Webull provides a variety of real-time ERNA stock news. You can receive the latest news about Ernexa through multiple platforms. This information may help you make smarter investment decisions.
About ERNA
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.